Everything you need to win Senti Biosciences — in one platform.
Who to reach, what to say, and why now on Senti Biosciences — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Senti Biosciences — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
Senti Bio Awarded $8 Million Grant from California Institute for Regenerative Medicines for Clinical Development of Logic Gated CAR-NK Cell Therapy
Jul 01, 2024•almost 2 years ago
Contract Type
partnership
South San FranciscoBiotechnology
Description
Senti Biosciences, Inc. (Nasdaq: SNTI) has announced that the California Institute for Regenerative Medicines has awarded an $8 million grant to support the ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia.
Company Information
Company
Senti Biosciences
Location
South San Francisco, California, United States
About
Senti Biosciences, Inc. is a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform.
South San FranciscoBiotechnology